GlassScriptPhysician profile
Priya Chaddah
NPI 1407480643
$2,523.00
in general payments reported to CMS, 2019-2025
19 companies · $713 in 2025
The $713 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $385 · 2023: $532 · 2024: $447 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.01 |
| Education | $129.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $648.39 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $359.43 | 2022-2023 | Farxiga, Lokelma |
| Medtronic, INC. | $304.15 | 2021-2023 | Ellipsys Vascular Access System |
| Mallinckrodt Hospital Products INC. | $220.00 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.27 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $129.93 | 2024-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $111.10 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $95.51 | 2021 | |
| Opko Pharmaceuticals, LLC | $92.08 | 2022-2023 | Rayaldee |
| Ani Pharmaceuticals, INC. | $72.45 | 2022-2023 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $69.55 | 2021-2022 | |
| Akebia Therapeutics INC | $68.21 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $53.42 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $27.03 | 2022 | |
| Genzyme Corporation | $24.80 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $21.08 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.28 | 2022 | |
| Travere Therapeutics, INC. | $8.32 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Chaddah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.